New combo attack on tough liver cancer
NCT ID NCT07364305
Summary
This study is testing a two-part treatment for advanced bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. It combines chemotherapy delivered directly to the liver (HAIC) with immunotherapy drugs (Durvalumab or Pembrolizumab). The main goal is to see if this combination can shrink tumors effectively and safely in 50 participants, potentially making surgery an option for some.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Eastern Hepatobiliary Surgery Hospital
RECRUITINGShanghai, Shanghai Municipality, 200438, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.